Blog

Croissy-Beaubourg and Montpellier, January 15, 2015 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, announces that it has renewed the Standby Equity Facility (SEF®) arranged with Société Générale, as approved by the shareholders’ annual meeting of April 8, 2014.

Michel Finance, Chief Executive Officer of Theradiag, comments: “We have used the entirety of the previous SEF® set up with Société Générale. Its proceeds have allowed us to prepare the international development of our LISA TRACKER portfolio, while limiting any dilution for our shareholders. We have decided to renew this SEF®, to further support our international activities and bring to market new theranostics tests, all while preserving our financial structure thanks to a limited discount”.     

Under the terms of the new SEF®, Société Générale has committed to subscribe to successive capital increases, issued by tranches over the next 24 months, within the global limit of 500,000 shares, i.e. 9.64% of the number of shares currently outstanding[1].

For each tranche, the issuance price will reflect the volume-weighted average price of shares for the three trading days immediately preceding the issue date, minus a discount of no more than 5%. This discount will enable Société Générale to instantly underwrite the shares despite possible market volatility. Acting as financial intermediary, Société Générale has no intention to remain a shareholder of the Company.

Should the entire standby equity facility be drawn down^[2], a shareholder currently owning 1.0% of the company’s share capital would see his or her share ownership reduced to 0.91%^[3].